Wegovy is semaglutide. Ozempic is semaglutide. Research-grade semaglutide is the same molecule. This guide explains the brand name confusion, the key differences in dose and approved indication, STEP clinical trial results, common side effects, and the landmark SELECT cardiovascular outcomes data.
Semaglutide, Wegovy, and Ozempic are all the same active molecule — a GLP-1 receptor agonist developed by Novo Nordisk. Wegovy is the brand name for semaglutide approved at 2.4 mg/week for chronic weight management in adults who are obese or overweight with at least one weight-related condition. Ozempic is the brand name for semaglutide approved at up to 2 mg/week for type 2 diabetes. Research-grade semaglutide is the same molecule available for research purposes only.
Novo Nordisk markets semaglutide under three brand names, each targeting a different indication and dose range. The active GLP-1 receptor agonist molecule is identical across all three. A common question is whether semaglutide vs Ozempic represents a meaningful difference — it does not; Ozempic is simply the brand name for the diabetes-indication formulation. Similarly, is semaglutide the same as Wegovy? Yes — Wegovy is the same molecule at a higher approved dose for weight management. For a comparison with tirzepatide, see the Semaglutide vs Tirzepatide comparison. For the full GLP-1 family background, see the GLP-1 Peptides guide.
| Name | Type | Dose | Indication | Approval |
|---|---|---|---|---|
| Ozempic | Brand (Novo Nordisk) | 0.5–2 mg/week SC | Type 2 diabetes | 2017 |
| Wegovy | Brand (Novo Nordisk) | 0.25–2.4 mg/week SC | Chronic weight management + CV risk reduction | 2021 |
| Rybelsus | Brand (Novo Nordisk) | 3–14 mg/day oral | Type 2 diabetes (oral) | 2019 |
| Research semaglutide | Research grade | Researcher-defined | Research purposes only | N/A |
One row per compound: the amount and schedule administered in a specific indexed study, who received it, and the paper. These are reports of what was done in that study, not recommendations, and several are animal or single-dose studies. Where no indexed human regimen exists we say so rather than print a number. Community "stacks" and cycle schedules are not reproduced on this site.
Research use only. Compound Review scores vendors on documentation — laboratory certificates, lot records, pricing and company identity. Nothing on this page is guidance on human or veterinary use, dosing or health outcomes.
| Compound | Regimen in the study | Population | Source |
|---|---|---|---|
| Semaglutide | 2.4 mg subcutaneous once weekly for 68 weeks (after dose escalation), plus lifestyle intervention | 1,961 adults with BMI ≥30 (or ≥27 with a weight-related condition), no diabetes — STEP 1 | PMID 33567185 Wilding et al., N Engl J Med 2021 |
Research use only. Compound Review scores vendors on documentation — laboratory certificates, lot records, pricing and company identity. Nothing on this page is guidance on human or veterinary use, dosing or health outcomes.
Semaglutide is a GLP-1 receptor agonist — a synthetic peptide that mimics glucagon-like peptide-1. GLP-1 is a naturally occurring incretin hormone released from intestinal L-cells after eating. By binding to GLP-1 receptors throughout the body, semaglutide activates multiple pathways. These pathways regulate blood sugar, body weight, and cardiovascular function.
Semaglutide delays stomach emptying, which reduces the rate of glucose absorption and promotes earlier satiety after meals. This mechanism contributes to both blood sugar control and reduced caloric intake.
GLP-1 receptors in the hypothalamus and brainstem regulate hunger and satiety signals. Semaglutide reduces appetite and food cravings by acting on these central nervous system pathways, leading to significant reductions in body weight.
Semaglutide stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner — meaning it only triggers insulin release when blood sugar is elevated. This mechanism reduces the risk of hypoglycemia compared to older diabetes medications.
Novo Nordisk launched Ozempic first (2017) for type 2 diabetes at doses up to 2 mg/week. Clinical trials then showed that a higher dose — 2.4 mg/week — produced clinically meaningful body weight reduction in adults who are obese or overweight. Novo Nordisk sought a separate approval under a new brand name: Wegovy. This was partly a regulatory strategy (separate indication, separate dosing device). It was also partly a commercial one (separate pricing and reimbursement pathway).
The result is widespread confusion. The same active GLP-1 receptor agonist molecule is sold under three brand names (Ozempic, Wegovy, Rybelsus) at different doses for different indications. Media coverage frequently conflates them. The only meaningful differences are the approved dose, the approved indication, and the titration schedule — not the molecule itself.
The STEP (Semaglutide Treatment Effect in People with Obesity) program was a series of Phase 3 clinical trials that established the efficacy of semaglutide 2.4 mg/week for chronic weight management. All trials used a 68-week treatment period with the standard titration schedule.
| Trial | N | Population | Body Weight Reduction | Notes |
|---|---|---|---|---|
| STEP-1 | 1,961 | Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidity | −14.9% | Placebo: −2.4%. First pivotal trial establishing Wegovy's weight management efficacy. |
| STEP-2 | 1,210 | Adults with type 2 diabetes and obesity/overweight | −9.6% | Placebo: −3.4%. Lower weight loss vs STEP-1 due to diabetes-related metabolic differences. |
| STEP-3 | 611 | Adults with obesity + intensive behavioral therapy | −16.0% | Behavioral therapy arm: −5.7%. Highest weight loss in the STEP program. |
| STEP-5 | 304 | Adults with obesity or overweight with comorbidity | −15.2% | 2-year durability data. Weight loss maintained at 2 years with continued treatment. |
| SELECT | 17,604 | Adults with obesity/overweight + established CV disease, no diabetes | −9.4% | Primary endpoint: 20% reduction in MACE. Led to CV risk reduction indication (2024). |
The SELECT trial (2023, N=17,604) was the first large-scale cardiovascular outcomes trial for a GLP-1 receptor agonist in adults without diabetes. Participants were adults with obesity or overweight and established cardiovascular disease. Semaglutide 2.4 mg/week reduced the risk of major adverse cardiovascular events (MACE) by 20% compared to placebo. MACE includes cardiovascular death, non-fatal heart attack, and non-fatal stroke. The median follow-up was 33 months.
This finding led to an expanded FDA indication for Wegovy in 2024: reducing the risk of serious cardiovascular events in adults with established cardiovascular disease who are obese or overweight. It was a landmark result because it demonstrated that the cardiovascular benefit of semaglutide is independent of its glucose-lowering effects.
Because both Wegovy and Ozempic are semaglutide, they share the same side effect profile. The higher dose used in Wegovy (2.4 mg vs 2 mg/week) produces a higher incidence of gastrointestinal side effects. The risk of side effects is highest during dose escalation and typically decreases with continued treatment.
| Side Effect | Wegovy (2.4 mg) | Ozempic (2 mg) | Notes |
|---|---|---|---|
| Nausea | 44% | ~20% | Most common; peaks during dose escalation |
| Diarrhea | 30% | ~9% | Dose-dependent; usually transient |
| Vomiting | 24% | ~9% | Reduces with continued use |
| Constipation | 24% | ~11% | Slowed gastric emptying mechanism |
| Abdominal pain | 20% | ~7% | Usually mild to moderate |
| Pancreatitis | Rare | Rare | Monitor for persistent severe abdominal pain |
| Gallbladder disease | ~2.6% | ~1.5% | Rapid weight loss increases gallstone risk |
| Thyroid C-cell tumors | Black box warning | Black box warning | Rodent data only; not confirmed in humans. Contraindicated in MEN2/MTC history. |
Semaglutide carries a black box warning for thyroid C-cell tumors (medullary thyroid carcinoma) based on rodent studies. This risk has not been confirmed in humans, but semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). This warning applies to all semaglutide formulations including Wegovy, Ozempic, and Rybelsus.
Research-grade semaglutide is the same GLP-1 receptor agonist molecule as Wegovy and Ozempic, synthesized to research-grade purity standards and verified by third-party certificate of analysis (COA). It is available for in vitro and in vivo research purposes and is not approved for human therapeutic use.
For researchers studying GLP-1 receptor agonism, metabolic syndrome, cardiovascular disease, obesity, or type 2 diabetes pathways, research-grade semaglutide provides the same molecular target as the clinical formulations at a fraction of the cost. Purgo Labs provides third-party tested semaglutide with full COA documentation.
Research-grade semaglutide is the same active molecule as Wegovy and Ozempic. It is not FDA-approved for human use and is sold for research purposes only. The molecular structure, mechanism of action, and pharmacokinetics are identical to the pharmaceutical products.
Wegovy is priced at approximately $1,300–$1,500/month in the US without insurance. The high cost reflects Novo Nordisk's R&D investment, patent protection, and limited manufacturing capacity. Research-grade semaglutide is significantly less expensive and is available from suppliers like Purgo Labs for research purposes.
The most common side effects of semaglutide (both Wegovy and Ozempic) are gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%). These are most pronounced during dose escalation and typically improve over time. Serious but rare risks include pancreatitis, gallbladder disease, and a theoretical risk of thyroid tumors based on rodent data (not confirmed in humans). Semaglutide carries a black box warning for thyroid C-cell tumors in patients with a personal or family history of medullary thyroid carcinoma or MEN2.
Purgo Labs provides research-grade semaglutide with third-party COAs. Use code HEALTH for 20% off.
Buy Semaglutide at Purgo Labs